Ernexa Therapeutics prices $10.5M public offering of 21M shares and warrants

Ernexa Therapeutics Inc.

Offering of 21M shares of common stock (or equivalents) and warrants to buy 21M shares at $0.50 per unit.
Gross proceeds expected ~$10.5M; net proceeds for development programs, working capital, and general purposes.
Warrants exercisable at $0.68/share, expire 5 years from issuance or 180 days after release of Phase 1 ERNA-101 data.
Brookline Capital Markets acted as exclusive placement agent; offering closed Feb 10, 2026.
Potential additional $14.3M if all warrants exercised on cash basis (no assurance given).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Ernexa Therapeutics Inc. entered into Warrant Agent Agreement with Computershare Inc. and Computershare Trust Company, N.A. (effective 2026-02-10).

Action: entry
Counterparty: Computershare Inc. and Computershare Trust Company, N.A.
Effective: 2026-02-10

Exact text from the filing

On February 10, 2026, the Company also entered into a Warrant Agent Agreement (the “Warrant Agent Agreement”) with Computershare Inc. and Computershare Trust Company, N.A. (collectively, “Computershare”),

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Ernexa Therapeutics Inc. entered into Purchase Agreement with certain investors (effective 2026-02-06).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Effective: 2026-02-06

Exact text from the filing

In connection with the Offering, the Company also entered into a securities purchase agreement (each, a “Purchase Agreement”) with certain investors who purchased Shares, Pre-Funded Warrants and Warrants in the Offering.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Ernexa Therapeutics Inc. entered into Placement Agency Agreement with Brookline Capital Markets, a division of Arcadia Securities, LLC (effective 2026-02-06).

Action: entry
Agreement: underwriting
Counterparty: Brookline Capital Markets, a division of Arcadia Securities, LLC
Effective: 2026-02-06

Exact text from the filing

On February 6, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Brookline Capital Markets, a division of Arcadia Securities, LLC

View on SEC.gov

Browse all material agreements →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-006227

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.